In the BioHarmony Drug Report Database

"Preview" Icon

Boceprevir

Victrelis (boceprevir) is a small molecule pharmaceutical. Boceprevir was first approved as Victrelis on 2011-05-13. It is used to treat chronic hepatitis c and hepatitis c in the USA. It is known to target lysosomal protective protein and Replicase polyprotein 1a. Victrelis’s patents are valid until 2027-11-11 (FDA).

 

Trade Name

 

Victrelis
 

Common Name

 

boceprevir
 

ChEMBL ID

 

CHEMBL218394
 

Indication

 

chronic hepatitis c, hepatitis c
 

Drug Class

 

Antivirals: serine protease inhibitors

Image (chem structure or protein)

Boceprevir structure rendering